Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate. Combination chemotherapy has a favorable risk/benefit ratio for patients with advanced endometrial adenocarcinoma, including patients with severe debilitation, if supportive care such as hospitalization, parenteral antibiotics, and platelet transfusions are available. New Adriamycin-based drug combinations have sufficient antitumor activity to warrant major prospective evaluation by oncology cooperative groups.
 ...
PMID:Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. 87 31

Four consecutive patients with measurable recurrent squamous cell carcinoma of the vulva were treated with Adriamycin, in small doses approximately 45 mg/square meter of body surface area every 3 weeks. Three patients achieved objective regression of nodal metastases and residual tumor with clinical subjective benefit. Tumor control was maintained for 32, 31+, and 28+ weeks.
 ...
PMID:Adriamycin treatment of advanced vulvar carcinoma. 87 32

Mitotic and labeling indices of bone marrow tumor cells were determined from patients with disseminated neuroblastoma. Although pretreatment values were variable, the median indices indicated that only a small proportion of tumor cells were proliferating. The pretreatment indices could not be correlated with presenting clinical features or with the response to chemotherapy. Studies were repeated after 7 daily doses of cyclophosphamide (150 mg/sq m) and serially after Adriamycin (35 mg/sq m) given on Day 8. Changes in the mitotic and labeling indices during the first course of therapy could be directly correlated with the clinical response as evaluated after 4 months of induction chemotherapy. In all patients who attained a complete or partial remission, an increase in these indices was observed after 7 days of cyclophosphamide. If this increase was associated with an observed kinetic effect of Adriamycin in the G1, S, and G2 phases of the cell cycle, a complete remission was attained. If, following Adriamycin, kinetic evidence of an effect was not present in all three phases of the cell cycle, only partial remission was attained. No clinical response to therapy was observed in those patients in whom the mitotic index and labeling index did not increase after 7 days of cyclophosphamide.
 ...
PMID:Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma. 90 20

A number of therapeutic agents including L-asparaginase, Actinomycin-D, CCNU, Hydroxyurea, 5-FU, Cis-platinum, Cyclophosphamide, orchiectomy, Adriamycin and DES alone and in various combinations has been applied against the Dunning R-3327 rat prostatic adenocarcinoma subline G. We have found a parallel between the results of this study and those of similar therapeutic application to the human tumor. We conclude that this animal model may prove to be a useful screening system for agents against human prostatic cancer.
 ...
PMID:Chemotherapy of the transplantable adenocarcinoma (R-3327) of the Copenhagen rat. 91 40

In C57B1/6 mice bearing the intramuscular Lewis lung carcinoma, single intravenous doses of Adriamycin showed an higher antineoplastic effectiveness on the primary tumor and its lung metastasis than equal doses of its analog Daunomycin. The in vitro cell-binding of Daunomycin to these tumor cells was higher than that of Adriamycin, but no differences in cytotoxicity were found between the two agents. Pharmacokinetic studies revealed that Adriamycin (and/or its metabolites) accumulated in the neoplastic tissue more promptly, in significantly greater quantities and for longer periods than Daunomycin. The possible importance of these findings in explaining the greater therapeutic activity of Adriamycin in experimental animals is discussed.
 ...
PMID:Antineoplastic activity and pharmacokinetics of adriamycin and daunomycin in tumor bearing mice. 91 49

Cytophotometric examinations of solid carcinomas of Ehrlich in mice don't show a considerable cyto-cinetic effect after administration of Vincristin. On the other hand, Adriamycin causes in the same tumor a significant stop in the G2 + M phase with a synchronization factor of 1,4 to 1,5 related to G2. The following experiment with the combined Adriamycin and radiotherapy demonstrates with a statistical significance lying about 5% that an immediate radiotherapeutic success can be obtained which is even increased by a partial synchronization. A considerably enriched G2 + M phase as a result of the administration of Adriamyzin is proven by a first cyto-cinetic examination of human cancerous tissue. A possible clinical therapy scheme is discussed.
 ...
PMID:[Experimental examinations about the proliferation and radiotherapy after administration of Vincristin and Adriamycin (author's transl)]. 91 5

A case is presented of primary endolymphatic stromal sarcoma of the uterus in a debilitated elderly patient. Surgical intervention was contraindicated. Radium therapy was unsuccessful. A 4-month course of treatment with doxorubicin (Adriamycin) resulted in disappearance of the tumor. The patient is living 19 months after the beginning of Adriamycin therapy.
 ...
PMID:Doxorubicin (adriamycin) therapy of uterine sarcoma without surgery in an elderly patient. 96 80

This set of experiments was designed to evaluate the effects of thiabendazole (TBZ), a relatively nontoxic thiazole derivative, on the delayed hypersensitivity response of normal mice, tumor-bearing mice, and mice immunosuppressed by radiation and chemotherapy. Normal mice treated with a single intraperitoneal injection (20 mg. per kilogram) of TBZ given on the day of challenge with 2,4 dinitrochlorobenzene (DNCB) had 41 percent greater swelling of the injected foot pad than did control animals. This increased immune reactivity could be transferred with spleen cells from TBZ-treated animals as well as with macrophages incubated in vitro with TBZ. Mice given sublethal radiation (450 r) had almost complete restoration of the delayed hypersensitivity response (90 percent of control) when treated with TBZ. The immunosuppressive effects of Adriamycin also could be reversed in a similar fashion. It is likely that the immune function of more than one population of spleen cells is amplified by TBZ treatment. The observed effects strongly suggest that thiabendazole may have a role as an adjunct in cancer therapy.
 ...
PMID:Thiabendazole: a potential adjuvant in cancer therapy. 98 82

Fourteen children with disseminated neuroblastoma were treated with segmental total-body irradiation and a combination of cyclophosphamide, vincristine and Adriamycin. Six others had localized tumors and were treated with either surgery alone or limited irradiation and chemotherapy. The main objective of the study was to find out if this aggressive therapy for disseminated neuroblastoma would be tolerated and would promote longer disease-free remissions and possibly, cures. Complete responses were obtained in all patients with localized tumors. Of the 14 patients with disseminated disease, three had complete responses, five had partial responses, two had objective responses, and four were classified as nonresponders. Survival rates for this group are poor. Only two patients are still alive, and the single patient who survives free of disease has had a complex clinical course that is only indirectly a result of treatment. The median survival for patients with disseminated tumor was 9 months, not appreciably different from earlier result. Although toxicity was clinically manageable, it interfered with the planned schedule of therapy. Continuous weight loss combined with severe bone marrow suppression due to irradiation prevented about 50% of the scheduled drug dose from being administered. This resulted in poor control of tumor outside of radiation ports and eventually led to progressive disease within previously irradiated sites. We conclude that irradiation used in this manner will not improve disease-free survival of children with disseminated neuroblastoma. It is essential that disseminated disease be controlled before extensive irradiation is attempted.
 ...
PMID:Total-body sequential segmental irradiation and combination chemotherapy for children with disseminated neuroblastoma. 100 Apr 65

The transplantable C1300 murine neuroblastoma has been characterized biochemically and an in vivo model for the screening of new therapeutic approaches to the treatment of neuroblastoma developed. Subcutaneous inoculation of A/J mice with 10)6) C1300 cells results in predictable tumor growth and animal death in 25 +/- 4 days. Tumor growth is Gompertzian, correlates with increases in tumor RNA and DNA content and with the rate of tumor DNA synthesis as measured by [3H] thymidine incorporation. The model proposed is based on the degree to which various therapeutic options are able to inhibit tumor DNA synthesis, and these observations have been confirmed autoradiographically. A single course of either cyclophosphamide (25, 50, 100 or 200 mg/kg), BCNU (2, 7.5, 15, or 30 mg/kg) or cytosine arabinoside (15, 30, 60, 90 mg/kg) resulted in dose-related inhibition of tumor DNA synthesis. The maximum decline in DNA synthesis that was produced by the highest dose of each agent was by 81%, 77% and 68% of untreated tumor values respectively. Adriamycin, however, even at lethal levels (10 mg/kg), did not elicit significant inhibition of tumor DNA synthesis. Radiotherapy (200 R, 500 R or 1000 R) also produced graded inhibition of tumor DNA synthesis. This model is potentially useful for the preclinical screening of therapuetic options in the treatment of neuroblastoma. Thus, single agent therapy, combination chemotherapy and combined radiotherapy and chemotherapy may be rapidly evaluated for possible clinical use.
 ...
PMID:Pharmacokinetic studies in the chemotherapy of neuroblastoma using the C1300 murine system. 101 81


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>